Interpretation of ACG clinical practice guideline in 2024:treatment of helicobacter pylori infection
WU Xinguo
ZHENG Ruhua
CHANG Xin
NIU Chunyan
ZHANG Fuyu
Abstract：Helicobacter pylori(H.pylori)infection is a prevalent global health issue that can lead to indiges-tion,peptic ulcer disease,and gastric cancer.With ongoing research advancements,significant progress has been made in the eradication of H.pylori.Based on these important findings from North America,the American College of Gastroenterology(ACG)has released updated clinical practice guideline(CPG),published in the American Journal of Gastroenterology in September 2024.Compared to previous guidelines,key updates include:increased resistance rates to critical antibiotics used for H.pylori treatment,such as clarithromycin and levofloxacin,which have reduced the efficacy of common treatment regimens containing these antibiotics;and research on novel treat-ment options for newly diagnosed patients,including new antibiotic alternatives(e.g.,rifampicin)or more potent next-generation gastric acid inhibitors(e.g.,potassium-competitive acid blockers,PCABs).These updates provide the latest evidence and reference for the clinical management of H.pylori infection.
Keywords：helicobacter pyloriinfectionmanagementthe American College of Gastroenterologyclinical practice guideline
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 459-464 )